Tilatamig samrotecan clinical trials
Also written AZD9592.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses tilatamig samrotecan has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Presage Biosciences (2) · AstraZeneca (1)
Often tested with
Tested in the same studies.
Rilvegostomig (2) · Volrustomig (2) · Sabestomig (2) · Pembrolizumab (1)
Studies
Open first, then newest update. How each study uses tilatamig samrotecan has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- First in Human Study of AZD9592 in Solid TumorsActive, not recruitingPhase 1AstraZenecaNCT05647122Written as AZD9592Report a problem
- PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCCCompletedEarly Phase 1Presage BiosciencesNCT06366451Written as AZD9592Report a problem
- Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesActive, not recruitingEarly Phase 1Presage BiosciencesNCT04541108Written as AZD9592Report a problem
Tested with established drugs · 1 — they are given beside it
Tested in a combination · 2 — another drug in the study is under test too
- PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCCCompletedEarly Phase 1Presage BiosciencesNCT06366451Written as AZD9592Report a problem
- Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesActive, not recruitingEarly Phase 1Presage BiosciencesNCT04541108Written as AZD9592Report a problem
Codes
What other systems call tilatamig samrotecan · ClinicalTrials.gg INT016117
- UNII (FDA) BL5C53FB6HTILATAMIG SAMROTECANOne source FDA
- NCI Thesaurus C192091Tilatamig SamrotecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | BL5C53FB6H | TILATAMIG SAMROTECAN | One source FDA |
| NCI Thesaurus | C192091 | Tilatamig Samrotecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.